Triomics raises $15M to revolutionize oncology workflows with GenAI platform

New Delhi: Triomics, a San Francisco-based company, has secured $15 million in funding to revolutionize oncology workflows through its innovative GenAI-powered platform.

The platform, driven by oncology-specialized generative AI models known as OncoLLMTM, aims to automate and streamline critical processes for cancer centers.

The company has raised from several Silicon Valley firms making pioneering investments in generative AI and healthcare, including Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator.

Manual chart review has long been a bottleneck in cancer centers, with staff spending hours per patient searching for suitable clinical trials or care pathways. Triomics’ co-founders, Sarim Khan and Hrituraj Singh, recognizing the need for a solution to tackle this challenge developed the OncoLLM™ in collaboration with the Medical College of Wisconsin. With the increasing complexity of oncology data, Triomics’ solution offers a breakthrough by processing free-text health records at scale, matching patients to clinical trials, and enhancing the overall quality of care operations in precision oncology.

This innovative technology swiftly identifies 90% of eligible clinical trial patients within minutes, a task that typically takes days or weeks for nurses. Their system also extracts structured data from unstructured notes with comparable or superior accuracy to leading models like GPT4 or Claude, at a fraction of the cost. Recent findings also show their information retrieval engine outperforms existing models by 1.5-2 times.

“Most of the solutions on the market today claim they use GenAI, but many lack published evidence. Triomics is setting themselves apart by taking a truly collaborative approach to co-developing these models,” said Bradley Taylor, Chief Research Informatics Officer at the Medical College of Wisconsin and Director of the CTSI Center for Biomedical Informatics.

Anai Kothari, a surgical oncologist at the Medical College of Wisconsin Cancer Center added: “The ability to quickly and accurately convert complex cancer data into a format that can be used to improve patient care is crucial. Triomics has been a great partner in integrating our suggestions and rigorously studying their approach to ensure safety.”

Triomics’ proprietary software, powered by OncoLLM™, seamlessly integrates with health system Electronic Health Records (EHRs) to execute specific clinical and administrative tasks. For instance, Triomics Prism facilitates patient-trial matching by prescreening oncology patients for relevant clinical trials, while Triomics Harmony supports quality reporting and precision oncology through curated EHR data.

Hrituraj Singh, CTO at Triomics, commented: “Our investments in our core areas of focus have been deliberate. We have successfully merged expertise in two complex functional areas: our AI researchers, who are specialized in customizing language models to specific domains, and our clinical staff, who have decades of oncology-specific experience. As a result, our software can complement the strengths of these advanced models while also proactively addressing potential flaws, all with the intricacies of cancer research and care in mind.”

“We differentiate ourselves by building tailored models specifically for oncology and pairing them with GenAI native workflows,” said Sarim Khan. “While other solutions address some of the use cases we’re working on, like patient-trial matching, they are broad based solutions that use or modify legacy technologies that have proven not to have the scalability or ROI the industry is requesting.” 

Recognizing the critical need for accuracy in oncology data, Triomics collaborates with leading academic cancer centers and researchers to develop performance and safety benchmarks for generative AI. The company’s partnerships with organizations like Oncology-focused LLM Training (COLT) and Cancer Informatics for Cancer Centers (CI4CC) Society underscore its commitment to advancing oncology research and practice.

Triomics’ future plans include publishing additional data on OncoLLM efficacy across diverse settings and patient populations, as well as developing software to address additional oncology use cases. With this latest funding round and ongoing innovations, Triomics is poised to drive significant advancements in cancer care and research.